Optimizing Identification of Lyme Disease Diagnoses in Commercial Insurance Claims Data, United States, 2016-2019

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Nov 20

PMID 39567874

Authors

Courtney C Nawrocki

Austin R Earley

Sarah A Hook

Alison F Hinckley

Kiersten J Kugeler

Affiliations

Soon will be listed here.

Abstract

Background: Commercial insurance claims data are a stable and consistent source of information on Lyme disease diagnoses in the United States and can contribute to our understanding of overall disease burden and the tracking of epidemiological trends. Algorithms consisting of diagnosis codes and antimicrobial treatment information have been used to identify Lyme disease diagnoses in claims data, but there might be opportunity to improve their accuracy.

Methods: We developed three modified versions of our existing claims-based Lyme disease algorithm; each reflected refined criteria regarding antimicrobials prescribed and/or maximum days between diagnosis code and qualifying prescription claim. We applied each to a large national commercial claims database to identify Lyme disease diagnoses during 2016-2019. We then compared characteristics of Lyme disease diagnoses identified by each of the modified algorithms to those identified by our original algorithm to assess differences from expected trends in demographics, seasonality, and geography.

Results: Observed differences in characteristics of patients with diagnoses identified by the three modified algorithms and our original algorithm were minimal, and differences in age and sex, in particular, were small enough that they could have been due to chance. However, one modified algorithm resulted in proportionally more diagnoses in men, during peak summer months, and in high-incidence jurisdictions, more closely reflecting epidemiological trends documented through public health surveillance. This algorithm limited treatment to only first-line recommended antimicrobials and shortened the timeframe between a Lyme disease diagnosis code and qualifying prescription claim.

Conclusions: As compared to our original algorithm, a modified algorithm that limits the antimicrobials prescribed and shortens the timeframe between a diagnosis code and a qualifying prescription claim might more accurately identify Lyme disease diagnoses when utilizing insurance claims data for supplementary, routine identification and monitoring of Lyme disease diagnoses.

References

Kugeler K, Schwartz A, Delorey M, Mead P, Hinckley A . Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021; 27(2):616-619. PMC: 7853543. DOI: 10.3201/eid2702.202731. View

Jones S, Conner W, Song B, Gordon D, Jayakaran A . Comparing spatio-temporal clusters of arthropod-borne infections using administrative medical claims and state reported surveillance data. Spat Spatiotemporal Epidemiol. 2012; 3(3):205-13. DOI: 10.1016/j.sste.2012.01.001. View

Tseng Y, DeMaria Jr A, Goldmann D, Mandl K . Claims-Based Diagnostic Patterns of Patients Evaluated for Lyme Disease and Given Extended Antibiotic Therapy. Vector Borne Zoonotic Dis. 2016; 17(2):116-122. DOI: 10.1089/vbz.2016.1991. View

Goodlet K, Fairman K . Adverse Events Associated With Antibiotics and Intravenous Therapies for Post-Lyme Disease Syndrome in a Commercially Insured Sample. Clin Infect Dis. 2018; 67(10):1568-1574. DOI: 10.1093/cid/ciy329. View

Tseng Y, Cami A, Goldmann D, DeMaria Jr A, Mandl K . Using Nation-Wide Health Insurance Claims Data to Augment Lyme Disease Surveillance. Vector Borne Zoonotic Dis. 2015; 15(10):591-6. DOI: 10.1089/vbz.2015.1790. View

Schwartz A, Hinckley A, Mead P, Hook S, Kugeler K . Surveillance for Lyme Disease - United States, 2008-2015. MMWR Surveill Summ. 2017; 66(22):1-12. PMC: 5829628. DOI: 10.15585/mmwr.ss6622a1. View

Rebman A, Wang L, Yang T, Marsteller J, Murphy S, Uriyo M . Incidence of Lyme Disease Diagnosis in a Maryland Medicaid Population, 2004-2011. Am J Epidemiol. 2018; 187(10):2202-2209. DOI: 10.1093/aje/kwy133. View

Beach C, Hart S, Nowalk A, Feingold B, Kurland K, Arora G . Increasing Burden of Lyme Carditis in United States Children's Hospitals. Pediatr Cardiol. 2019; 41(2):258-264. DOI: 10.1007/s00246-019-02250-9. View

Schiffman E, McLaughlin C, Ray J, Kemperman M, Hinckley A, Friedlander H . Underreporting of Lyme and Other Tick-Borne Diseases in Residents of a High-Incidence County, Minnesota, 2009. Zoonoses Public Health. 2016; 65(2):230-237. DOI: 10.1111/zph.12291. View

10.

Adrion E, Aucott J, Lemke K, Weiner J . Health care costs, utilization and patterns of care following Lyme disease. PLoS One. 2015; 10(2):e0116767. PMC: 4317177. DOI: 10.1371/journal.pone.0116767. View

11.

Cocoros N, Kluberg S, Willis S, Forrow S, Gessner B, Nutt C . Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA. Emerg Infect Dis. 2023; 29(9):1772-1779. PMC: 10461665. DOI: 10.3201/eid2909.221931. View

12.

Nelson C, Saha S, Kugeler K, Delorey M, Shankar M, Hinckley A . Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005-2010. Emerg Infect Dis. 2015; 21(9):1625-31. PMC: 4550147. DOI: 10.3201/eid2109.150417. View

13.

Steere A, Strle F, Wormser G, Hu L, Branda J, Hovius J . Lyme borreliosis. Nat Rev Dis Primers. 2016; 2:16090. PMC: 5539539. DOI: 10.1038/nrdp.2016.90. View

14.

Schwartz A, Shankar M, Kugeler K, Max R, Hinckley A, Meltzer M . Epidemiology and cost of Lyme disease-related hospitalizations among patients with employer-sponsored health insurance-United States, 2005-2014. Zoonoses Public Health. 2020; 67(4):407-415. PMC: 7521202. DOI: 10.1111/zph.12699. View

15.

Wormser G, Dattwyler R, Shapiro E, Halperin J, Steere A, Klempner M . The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43(9):1089-134. DOI: 10.1086/508667. View

16.

Schwartz A, Kugeler K, Nelson C, Marx G, Hinckley A . Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021; 27(2):499-507. PMC: 7853566. DOI: 10.3201/eid2702.202728. View

17.

Rebman A, Yang T, Wang L, Marsteller J, Murphy S, Uriyo M . Outpatient visits before and after Lyme disease diagnosis in a Maryland employer-based health plan. BMC Health Serv Res. 2023; 23(1):919. PMC: 10466890. DOI: 10.1186/s12913-023-09909-3. View

18.

Lantos P, Rumbaugh J, Bockenstedt L, Falck-Ytter Y, Aguero-Rosenfeld M, Auwaerter P . Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Rheumatol. 2020; 73(1):12-20. DOI: 10.1002/art.41562. View

19.

Sickbert-Bennett E, Weber D, Poole C, MacDonald P, Maillard J . Utility of International Classification of Diseases, Ninth Revision, Clinical Modification codes for communicable disease surveillance. Am J Epidemiol. 2010; 172(11):1299-305. DOI: 10.1093/aje/kwq285. View

20.

Mead P . Epidemiology of Lyme disease. Infect Dis Clin North Am. 2015; 29(2):187-210. DOI: 10.1016/j.idc.2015.02.010. View